SB-218078
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


SB-218078
Description :
SB-218078 is a potent, selective, ATP-competitive and cell-permeable checkpoint kinase 1 (Chk1) inhibitor that inhibits Chk1 phosphorylation of cdc25C with an IC50 of 15 nM. SB-218078 is less potently inhibits Cdc2 (IC50 of 250 nM) and PKC (IC50 of 1000 nM) . SB-218078 causes apoptosis by DNA damage and cell cycle arrest[1][2][3].UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Apoptosis; CDK; Checkpoint Kinase (Chk) ; PKCType :
Reference compoundRelated Pathways :
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; TGF-beta/SmadApplications :
Cancer-Kinase/proteaseField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/sb-218078.htmlPurity :
98.30Solubility :
10 mM in DMSOSmiles :
O=C1NC(C(C2=C3N(C4CCC5O4)C6=CC=CC=C62)=C1C7=C3N5C8=CC=CC=C78)=OMolecular Formula :
C24H15N3O3Molecular Weight :
393.39Precautions :
H302, H315, H319, H335References & Citations :
[1]Jackson JR, et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 2000 Feb 1;60 (3) :566-72.|[2]Murga M, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011 Nov 27;18 (12) :1331-1335.|[3]Preet R, et al. Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016 Apr 1;105:23-33.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedIsoform :
Chk1; PKCCAS Number :
[135897-06-2]

